This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
First sentence of release should read: Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the company will report financial results for the three months ended September 30, 2013, after the close of trading on Thursday, November 7th (sted before the opening of trading).
The corrected release reads:
OPEXA THERAPEUTICS ANNOUNCES NEWS RELEASE AND CONFERENCE CALL SCHEDULE TO DISCUSSTHIRD QUARTER 2013 FINANCIAL RESULTS
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the company will report financial results for the three months ended September 30, 2013, after the close of trading on Thursday, November 7th. The company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 5:00 P.M. EST on Thursday, November 7
Conference Call and Webcast Details
To listen to the conference call, dial in approximately ten minutes before the scheduled 5:00 P.M. time to (253)237-1170 or toll free at (877)372-0867. Please reference conference ID # 94585914 or Opexa Therapeutics Earnings Call.
A live webcast of the call can also be accessed
here or via the webcast link on the Investor Relations page of Opexa's website (
There will be a Question & Answer session following management commentary.
Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. The Company’s leading therapy candidate, Tcelna
®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.
About Multiple Sclerosis (MS)
MS is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide.